{Reference Type}: Case Reports
{Title}: Case Report: Pirfenidone in the Treatment of Post-COVID-19 Pulmonary Fibrosis.
{Author}: Zhou X;Yang D;Kong X;Wei C;LvQiu S;Wang L;Lin Y;Yin Z;Zhou Z;Luo H;
{Journal}: Front Med (Lausanne)
{Volume}: 9
{Issue}: 0
{Year}: 2022
{Factor}: 5.058
{DOI}: 10.3389/fmed.2022.925703
{Abstract}: <B>UNASSIGNED: </B>Pulmonary fibrosis is one of the sequelae of the COVID-19, which seriously affects the quality of life of survivors. Currently, there are no optimal evidence based guidelines targeting this population.<BR><B>UNASSIGNED: </B>We report a 66-year-old female patient without underlying comorbidities admitted to Changsha Public Health Center because of COVID-19. During hospitalization, she developed co-bacterial infection and acute respiratory distress syndrome, and received broad-spectrum antibacterial therapy, invasive mechanical ventilation and extracorporeal membrane oxygenation. After the acute phase, she developed post-COVID-19 pulmonary fibrosis subsequently treated with pirfenidone. Over 96 weeks after pirfenidone treatment, her modified Medical Research Council Dyspnea level improved to 2 from 4 at discharge. Her 6 minutes walk test distance, total lung capacity, and diffusion capacity for carbon monoxide all increased. Chest CT performed on 2 years after illness onset showed regressing fibrosis. The Hospital Anxiety and Depression Scale, Athens Insomnia Scale, and 36-Item Short Form Health Survey questionnaire all improved.<BR><B>UNASSIGNED: </B>Post-COVID-19 pulmonary fibrosis is a challenging consequence of COVID-19, and our case suggests that pirfenidone may be an effective treatment option.